![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Departments of Pharmaceutical/Medicinal Chemistry I (A.S.) and Pharmacology and Toxicology (R.S.), School of Pharmacy, University of Regensburg, Regensburg, Germany; and Faculty of Chemistry and Pharmacy, University of Regensburg, Regensburg, Germany (H.-J.W.)
There are species differences between human histamine H1 receptor (hH1R) and guinea pig (gp) histamine H1 receptor (gpH1R) for phenylhistamines and histaprodifens. Several studies showed participation of the second extracellular loop (E2-loop) in ligand binding for some G protein-coupled receptors (GPCRs). Because there are large species differences in the amino acid sequence between hH1R and gpH1R for the N terminus and E2-loop, we generated chimeric hH1Rs with gp E2-loop (hgpE2H1R) and gp N terminus and gp E2-loop (hgpNgpE2H1R). hH1R, gpH1R, and chimeras were expressed in Sf9 insect cells. [3H]Mepyramine binding assays and steady-state GTPase assays were performed. In the series hH1R > hgpE2H1R > hgpNgpE2H1R, we observed a significant decrease in potency of histamine 1 in the GTPase assay. For phenoprodifen 5 and the chiral phenoprodifens 6R and 6S, a significant decrease in affinity and potency was found in the series hH1R > hgpE2H1R > hgpNgpE2H1R. In addition, we constructed new active-state H1R models based on the crystal structure of the human β2-adrenergic receptor (hβ2AR). Compared with the H1R active-state models based on the crystal structure of bovine rhodopsin, the E2-loop differs in its contact to the ligand bound in the binding pocket. In the bovine rhodopsin-based model, the backbone carbonyl of Lys187 (gpH1R) interacts with large histaprodifens in the binding pocket, but in the hβ2AR-based model, Lys187 (gpH1R) is located distantly from the binding pocket. In conclusion, the differences in N terminus and E2-loop between hH1R and gpH1R exert an influence on affinity and/or potency for histamine and phenoprodifens 5, 6R, and 6S.
Address correspondence to: Dr. Andrea Straßer, Department of Pharmaceutical and Medicinal Chemistry I, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany. E-mail: andrea.strasser{at}chemie.uni-regensburg.de